Zura Bio price target raised to $12 from $11 at Chardan

Chardan analyst Daniil Gataulin raised the firm’s price target on Zura Bio (ZURA) to $12 from $11 and keeps a Buy rating on the shares following the Q3 report. The firm says tibulizumab’s Phase 2b in systemic sclerosis is on track for a Q4 initiation.